Phase III Trials of Standard Chemotherapy with or without Bevacizumab for Ovarian Cancer: A Meta-Analysis

BACKGROUND: Platinum-based standard chemotherapy improves survival of ovarian cancer (OC), but the five-year survival rate remains below 50%. Antiangiogenic agents (7.5 or 15 mg/kg Bevacizumab, Bev) plus to standard chemotherapy improve progression-free survival (PFS) not overall survival (OS) in co...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Mingyi, Yu, Ping, Qu, Xiujuan, Liu, Yunpeng, Zhang, Jingdong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3853655/
https://www.ncbi.nlm.nih.gov/pubmed/24324725
http://dx.doi.org/10.1371/journal.pone.0081858

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3853655/
https://www.ncbi.nlm.nih.gov/pubmed/24324725
http://dx.doi.org/10.1371/journal.pone.0081858

Ejemplares similares